Loading…
← CockpitCompetitor Analysis › 002688.SZ Jinhe Biotechnology Co., Ltd. Class AOpen in the cockpit ↗

Jinhe Biotechnology Co., Ltd. Class A002688.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 72
Mkt cap
$550M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$4.94M
20-day average traded
Fwd P/E
8.9×
forward earnings
ROIC−WACC
+0.7 pp
WACC 5.0%
Hurdle
-9 pp
Req g minus delivered
Next earnings
167 days
4 May 2027
Close · CNYCN¥4.78
1D+5.3%
1W+3.5%
1M-3.6%
3M-8.6%
6M-18.7%
YTD-19.7%
1Y-22.6%
ATR %2.8%
52w lowhigh31.7% off high

What Jinhe Biotechnology does

Employees: 2,718

Jinhe Biotechnology at a glance

Size Jinhe Biotechnology (002688.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $550M, the 3461st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.78 on 18 Nov 2026.

Performance Over six months the shares fell 18.7%, against -18.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 19 in its peer set.

Growth Revenue grew 7.0% over the last twelve months (peer median +0.7%); the operating margin is 5.1% (peer median 6.8%).

Valuation It trades at 8.9× forward earnings against a peer median of 11.3× (cheapest of 10).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026002688.SZ 82Peer median 81
Six months, rebased to 100: Jinhe Biotechnology against the median of its 20 peers (local-currency closes).

Jinhe Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.94BCN¥2.87BCN¥2.37BCN¥2.16BCN¥2.11B
Revenue growth—+21%+10%+3%—
Gross profitCN¥1.16BCN¥869MCN¥709MCN¥565MCN¥539M
EBITDAn/aCN¥542MCN¥384MCN¥331MCN¥288M
Net incomeCN¥21.6MCN¥27.6MCN¥100MCN¥86.5MCN¥75.6M
Free cash flowCN¥141MCN¥147MCN¥135M-CN¥256M-CN¥280M
Capital expenditureCN¥372MCN¥320MCN¥362MCN¥457MCN¥402M
Total debtCN¥2.30BCN¥2.45BCN¥2.52BCN¥2.37BCN¥1.61B

Quarterly statements and history in the cockpit →

Jinhe Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%4559ZVRA003850ACRS002393MOREPENLABSENORES688356603222ENTXALMSSUPRIYA361322562157002688.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jinhe Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×40×4559ZVRA003850002393SENORES688356SUPRIYA36132157002688.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jinhe Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%4559ZVRA003850002393688356000919SUPRIYAEVONILE3613002688.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jinhe Biotechnology is the large dot.

Jinhe Biotechnology competitors and peer comparison

How Jinhe Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jinhe Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure002688.SZPeer medianRank in peer set
1-month return-3.6%-11.4%4th highest of 20
6-month return-18.7%-18.3%10th highest of 19
Distance from 52-week high-31.7%-42.8%5th highest of 20
Revenue growth (TTM)+7.0%+0.7%9th highest of 20
Operating margin5.1%6.8%8th lowest of 19
Forward P/E8.9×11.3×cheapest of 10
Growth the price implies (Req g, 7 yrs)1.0%-3.1%5th most demanding of 10
Growth delivered (Del g)+9.7%+11.1%5th lowest of 10
Hurdle (Req g minus delivered)-8.7 pp-9.9 pp5th most demanding of 10
ROIC minus cost of capital+0.7 pp-3.5 pp4th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%8.9×1.0%+9.7%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%n/an/an/a
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%32.2×n/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%n/a2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%36.2×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%n/a49.3%-1.5%
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a

Questions

Which companies are Jinhe Biotechnology's closest peers?
The cockpit's peer set: Zeria Pharmaceutical (4559.T), Zevra Therapeutics (ZVRA), Boryung (003850.KS), Aclaris Therapeutics (ACRS), Tianjin Lisheng Pharmaceutical (002393.SZ), Morepen Laboratories (MOREPENLAB.NS), Zhong Zhu Healthcare (600568.SS), Senores Pharmaceuticals (SENORES.NS).
Is Jinhe Biotechnology expensive compared with its peers?
On forward p/e it trades at 8.9× against a peer median of 11.3×, cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Jinhe Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -18.7% against -18.3% for the median peer; over one year -22.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.